<SEC-DOCUMENT>0001171843-11-003181.txt : 20120110
<SEC-HEADER>0001171843-11-003181.hdr.sgml : 20120110
<ACCEPTANCE-DATETIME>20111028160030
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001171843-11-003181
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20111028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Capstone Therapeutics Corp.
		CENTRAL INDEX KEY:			0000887151
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				860585310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		6022865520

	MAIL ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOLOGIC CORP
		DATE OF NAME CHANGE:	19940211
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
<head>
    <title>corresp_102811.htm</title>
    <!--Licensed to: NASDAQ-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><img src="logo.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">October 28, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Jeffrey Riedler</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Assistant Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">United States Securities and Exchange Commission</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">100 First Street, N.E.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, DC 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: ; ">
<tr valign="top">
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Re:&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Capstone Therapeutics Corp. (the &#8220;Company&#8221;)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">Item 1. Business</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Patents, Licenses and Proprietary Rights, page 6</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: ; ">
<tr valign="top">
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form </font>10-K</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Filed on March 29, 2011</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">File No. 001-33560</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Your letter dated October 21, 2011.</font></div>
</div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following is our response to your letter dated October 21, 2011. We have included your specific comment prior to our response to facilitate your review.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 1. Business</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Patents, Licenses and Proprietary Rights, page 6</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Please revise your disclosure to expand your discussion of your agreements with University of Texas and Arizona State University to describe for each the termination provisions of the agreements and the royalty rates due on sales of future products and all other material payments made or required to be made pursuant to the terms of each agreement. Further, please file a copy of the license agreement with Washington University that you have assumed and revise your disclosure to expand your discussion of your agreement with Washington University to include the termination provisions of the agreement and the license maintenance payments made to date and payable annually and the royalty rate. Alternatively, please provide us with a detailed analysis which supports your conclusion that your business is not substantially dependent on this license agreement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Our Response:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The license agreement for AZX100 between the Arizona Science &amp; Technology Enterprises, LLC, an Arizona limited liability company, dba Arizona Technology Enterprises, LLC (&#8220;AzTE&#8221;) (the technology entity for Arizona State University) and OrthoLogic Corp. (OrthoLogic Corp. changed its name to Capstone Therapeutics Corp. on May 21, 2010) was filed as Exhibit 10.5 to the Company&#8217;s Registration statement on Form S-3 filed with the Securities and Exchange Commission (SEC) on April 25, 2006 (Listed in Exhibit Index to the Annual Report on Form 10-K filed on March 29, 2011 as Exhibit 2.4).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1275 West Washington Street, Suite 101 &#9679; Tempe, AZ&#160;&#160;85281 &#9679; Office 602-286-5520 &#9679; Fax 602-926-2641&#9679;www.capstonethx.com</font></font></div>
</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SEC Correspondence</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">October 28, 2011</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 2 of 4</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The license agreement for Chrysalin between the Board of Regents (&#8220;Board&#8221;) of The University of Texas System, an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701 (&#8220;System&#8221;), through its component institution, The University of Texas Medical Branch at Galveston (&#8220;University&#8221;), and Chrysalis Biotechnology, Inc.<font style="DISPLAY: inline; FONT-SIZE: 10pt">,</font> was filed as Exhibit 10.1 to the Company&#8217;s Registration statement on Form S-4 filed with the Securities and Exchange Commission (SEC) on June 3, 2004 (the &#8220;S-4&#8221;) (Listed in Exhibit Index to the Annual Report on Form 10-K filed on March 29, 2011 as Exhibit 2.1). As part of the purchase transaction described it the S-4, the License agreement was assigned to OrthoLogic Corp.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is a development stage research and development company with no current products approved for marketing by the FDA. These contracts were deemed by the Company to be material contracts, not because of the financial terms, but because the intellectual property covered by the contracts gives the Company protection against competition for potential future products. As shown in the publicly available contracts, the royalty rates on product sales are 3% (AZX100) and 3.3% (Chrysalin) with both contracts providing for an additional payment of 5% on non-product sale revenue, excepting the proceeds from the sale of the Company. The payment obligations were not deemed material to the understanding of the Company&#8217;s business. It is currently not expected that the Company will have products approved for marketing before 2016, if ever, and accordingly, the contract obligations are not currently affecting reported results.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The non-Exclusive License Agreement between Washington University (Licensor) and AzERx (Licensee), assigned to OrthoLogic Corp. as part of the purchase transaction described in the Asset Purchase Agreement and Plan of Reorganization by and between OrthoLogic Corp. and AzERx, dated February 23, 2006, filed as Exhibit 10.5 to the Company&#8217;s Registration statement on Form S-3 filed with the Securities and Exchange Commission on April 25, 2006 (Listed in Exhibit Index to the Annual Report on Form 10-K filed on March 29, 2011 as Exhibit 2.4) was not deemed to be a material contract by the Company as intellectual property covered by the contract does not give the Company protection against competition for potential future products, as it is non-exclusive, the maximum royalty rate is only 2% of product sales and the underlying patents expire in 2018. Given it is not expected that the Company will have products approved for marketing before 2016, if ever, the contract and related royalty obligations will be effective for a very short period and not be expected to have a material impact on our operations in any period. AXZ100 is a two part molecule consisting of a cargo and a carrier (protein transduction domain or &#8220;PTD&#8221;). We mention the contract in our filings only because we often are asked where the PTD originated. The PTD was provided by Washington University.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The instructions to Form 10-K Part 1, Item1. Business are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furnish the information required by Item 101 of Regulation S-K (&#167;229.101 of this chapter) except that the discussion of the development of the registrants business need only include developments since the beginning of the fiscal year for which the report is filed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;As noted in our Form 10-K filed on March 29, 2011, we qualify as a Smaller Reporting Company and thus our disclosures are governed by Regulation S-K, Item 101, (h) (4) (vii) as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4) Business of Smaller Reporting Companies: Briefly describe the business and include, to the extent material to the understanding of the smaller reporting company:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1275 West Washington Street, Suite 101 &#9679; Tempe, AZ&#160;&#160;85281 &#9679; Office 602-286-5520 &#9679; Fax 602-926-2641&#9679;www.capstonethx.com</font></font></div>
</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SEC Correspondence</font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">October 28, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page&#160;3 of 4</font></div>
</div>

<div>&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(vii)&#160;&#160;&#160;&#160;&#160;Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including duration.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The disclosure in our Form 10-K filed March 29, 2011 was as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Patents, Licenses and Proprietary Rights</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As part of our purchase of CBI on August 5, 2004, the license agreements between CBI and OrthoLogic for the development, use, and marketing of the therapeutic products utilizing Chrysalin were replaced by a direct license agreement between OrthoLogic and the University of Texas.&#160;&#160;Subsequently, we entered into an agreement whereby the University of Texas assigned to us certain patents previously exclusively licensed to us.&#160;&#160;We must pay the University of Texas royalties on future sales of products, sublicense fees and various other fees in connection with filing and maintaining Chrysalin-related patents. This obligation will expire upon the expiration of the subject patents. Chrysalin has been patented in the United States and in some other countries for a number of methods of use, including cardiovascular indications.&#160;&#160;A composition of matter patent covering European countries expired in 2007 and the corresponding United States patent expires in 2011.&#160;&#160;Our other patents for Chrysalin expire between 2021 and 2024.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As part of the February 27, 2006 AzERx transaction, we acquired a license from AzTE, an affiliate of Arizona State University, for worldwide rights to AZX100 for all indications.&#160;&#160;Under the license agreement with AzTE, we are required to pay patent filing, maintenance and other related patent fees as well as royalties on future sales of products that contain AZX100.&#160;&#160;These obligations will end on the expiration of the last patent.&#160;&#160;The license is supported by patents that expire from 2022 to 2024.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As part of the February 27, 2006 AzERx transaction we also acquired a non-exclusive license from Washington University for transduction domain carrier patents which form part of AZX100.&#160;&#160;Under the license, we are required to pay license maintenance payments and royalties on future sales of products that contain the licensed technology.&#160;&#160;These obligations will end on the expiration of the last covered patent.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Capstone Therapeutics is a registered United States domestic trademark of Capstone Therapeutics Corp.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;----------------------------------------</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">It is well known that intellectual property obligations continue to the expiration of the intellectual property right. Furthermore, we purchased the University of Texas patent rights and neither AzTE nor Washington University has the right to terminate our licenses. Accordingly, we believe that discussion of the termination provisions is not material to the understanding of our business. We believe our disclosures are adequate, as we do list the critical expiration dates for our patent protection and correspondingly, the expected intellectual property contract obligation periods. We specifically state in the first two paragraphs that </font>the obligations will end on the expiration of the last patent.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1275 West Washington Street, Suite 101 &#9679; Tempe, AZ&#160;&#160;85281 &#9679; Office 602-286-5520 &#9679; Fax 602-926-2641&#9679;www.capstonethx.com</font></font></div>
</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SEC Correspondence</font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">October 28, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page&#160;4 of 4</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company acknowledges that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is responsible for the adequacy and accuracy of the disclosure in the filing;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Please contact me if we can be of further assistance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sincerely,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;&#160;&#160;Les M. Taeger</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Les M. Taeger</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Senior Vice President and Chief Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Capstone Therapeutics Corp</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1275 West Washington Street, Suite 101 &#9679; Tempe, AZ&#160;&#160;85281 &#9679; Office 602-286-5520 &#9679; Fax 602-926-2641&#9679;www.capstonethx.com</font><br>
</div>

<div>
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_X1`017AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!@````
M`0```&`````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q,3HQ,#HR
M-B`Q-3HQ,SHR,0```````Z`!``,````!__\``*`"``0````!````NJ`#``0`
M```!````10`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```[:````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`.P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]322224I))))2DDDI"2E))G/:UI<XAK0
M)).@6;9UEMSS5TVI^;8#!>W2II_E7GV_YB9/)&.Y^SU2_P`1(B2Z1('/`Y6=
M=UF@6FC#:[-R1S75JT3I[[?H-7+=9^M.(S(^PV6OZUU(F&]'Z:)K!_.;DY(:
M_P"C_A-OZ6K_`$:I7=*ZUU!GI_67)'3\(P6?5[IA#7.'_FPRI=^XQS]]E^__
M``7H/3)&8B92(PX_WIGUR_ZG^BN$1="YR[#Y7H\3ZTVV6VP*,^FH_IA@6MML
MH_DWU`_I/^.9^C6SA=3P>H5EV)<VP@>YG#Q_6K/N7GF5T7H;K&#'H/1[L9H&
M+G]/+VVU:.;^F:YWZ\WW?I;-]&7_`,*IWY76.G`977L4=5P!K7]8>E0V]@&[
MW9M#=C?9[-_J,J]+_376*/%D]SB]C)[E'7%F'!E_P>#]%?.%5QQX/ZT?5'_$
M?3)27*]'Z_E9&/\`:>GY%?7\%D;G5>S*KG_3T/VN_-_.;[UMX'6NGYYVTV[;
MFZ/HLEEC3^ZZM\*6.>/%PR!QY/W)^G_G?)+_``6,P-6*D.X;Z26X3'=)2K5)
M)))*4DDDDI__T/4TI\EG]>ZWA]"Z5?U/,/Z*D#:QOTGO=[:J:_Y=C_\`THLW
M!Z)G=3K;F?62ZXWW-#F],HN?3CX[3[FU/^S/J?F9#?\`#W9%EK/4_F:_32K2
MU/13^*4KE/K#]7^JX'3;\OZK9^5C9%;9=AOL=DU6,&MK:69WVE^-D;/YK[.[
M\ST?3]_J5]-DY%6+CW9-SMM..QUMCO!K!O<?P1(4DGR0LC[3L/V4,]0][-T#
M^RSZ:Y3ZK974,/ZR=3Z/U-[WOSZJ^KXK+#.SU?T>=C-<7?0Q[ME--?\`HZEO
M?62BNWH/4`\$;<>VQI:2UP>QK[:[&/K+7-<UXW(2C9KNH'JQ/1WW`V=2N.8\
M:LHUKH!'`V-G_.L6%F_5CZT];L^S=6ZE3TWI!EIP>E!P<]I+ALNR;V,_,=[O
M9Z%G_<9$^K/0\;J?U2Z=D/MOHSKL</\`MM5UK;18[_#;O4_2?\7;^B6=A_6W
MJ?4OJYT9EUWV3-ZGG_LS*SJF@>UI=ZMN-S75E9>VNJM_I>FRU]UE5=?Z-"&,
M0),!K?JE+67VI,B=_L>BQ/JU3TC%^Q_5^JGI]3A^ENASKWG^7<[W_G?GN_XK
MTD`?5G,Y]:N3).CB23^<YWTE:R?JW0746X-^1AWX]U=A>,BY[;6,>'649C+;
M'_:67LW;M_Z7_A$V/]5,$/R;,F[*MLR<BV\M;E9%3&"UYL;573CW55-VM+=_
MM]]BCR<OBR&YF4OK^Q=#+*&D:#1M^J>>YY>V^KRT<(@*>']7>LX%WJXF756X
M_2:0[:^/S;&?]^_G?^$5#ZK=/JZCF==KS;\RYF#U&S'Q6G-R@&5-#=M;=N0W
M_I+;IQ<#ZLX_4^H6WVG#,9+_`%K'W/9Z=;:G5LMR'V76[MC/28^S^<L47^C^
M7C(R`D)>$B%QYC(11HAS.I_4'!S+6]1Z?8>A];`DY6`2*W.//JT#T]S+/S_Y
MK?\`X7UE9PNB]:R&>G]9QAY;JV@59^)OJR"?^%9L97[O^"?Z?_`*71\7.ZYA
MU=5ZS9;37EM]7%Z;CV.JKKI?[Z?M#Z#7D9>4ZO\`27>J_P!#_1X]:M7_`%=8
MQA?TG)OZ=DMUK<VQ]E1/89&)D/LIMK_TFWT[O^&5J48RCP3J?3U>K?\`K,0)
M!L:,L;"ZQAOV59;<O%X#<D$6-'@V^KZ7_7%JC29^?DL;ZN]8'7,"^O+K;3G8
MEC\/J6,TDM;:SV/-3OI_9[OYREW]CU/T:Y_&S\CZH]:R*<BU]OU6R,D4576O
M=8["O-=-FVRZW<]N%>ZW8W>_]'_VY]H;CQ"-@$Z?HD\0_P`'B3*5T2]SN3SY
M%1<QMC'5O&YKP6N'B'?27-4=)PS]4<RD>H-IR[&6^J\VM?6^^NFUE[G.MWU,
MK8VM/`NO-#T_R27"_4'HG3^K_53!ZAU(79.9;ZPLN=D7R=MUM;/HW-;[6-:N
MEZ5T&CI.;D68=EOV7)K8/L]MMEH8]A>2ZG[0^QU?JMM_2>[_``:1`M3_`/_1
MVOKT]V7]:OJKTAQ_5W91RKF'4.-19Z>X?U&W,_ZZNY`'^OBN%_QC568.?T'Z
MS`$X_2\H,S-HDBJUS/?Q]'V6U?U[:EW#'-<`YAW,<):X&00=01_)1/RQ[*ZL
MED?6,W6U8W3<:MEUN;<W?58]U;#101DY/J6,KO\`T=NRO%?^C_[4K7*Q&OR_
M^<%N7E5.&'52<;$<QEMC]Q?ZF78]C*=C&7[*&U>G;_@?^VT%%POK8_JN#U#I
M/UIRL6C'JZ5>*LNRF]UQ./E'[/=ZC7XV+_,[OT?N_P`,NHZ]KT'J4:C[)?K_
M`-;L57ZP-KZIT3-Z;7399;ETOI8+*;F-#W`^E8Y_HOVMJM_2*C3^VA]4W=)R
MJ1;U,8IPVV,%_HOEAH;D66OQM[-M?Z2WV?SJ.]'L5(/JIB=6ROJ=TNFKJ#<2
MBS'8"ZFC]8##RVK(MOMI99_POV3^PM3(^I_0;_J^WZO.Q]G3ZQ^BVG])6^7.
M&35:[=^L;WO]_P#+V6?HOT:']5FW]*Z%B=-SZW-OQ&"HNIKNLK>UI.RQKG45
MN][?S'J75+.I/S\+-Z586C';:S(Q;Z,@,N;8:BR;*Z7NH?3Z-CJ[O3L_\%>D
M;L^:G%/4?K+]3KJ6]9O_`&S]7K'MI'42(RL8O(;7]LY]>K]^SW_\9_-8UO;-
MF3\=%S75J\SKN/7T_J&-]EZ<^RNS,:QM]UEHJ>V]F-7MQJ?1KLMK9ZESG>IL
M]C*O\(MQW4*8)#+R>P%%W_5>DA+6NBGG?J1_RA]:/_3M;^1J-_C)QK\GZD]3
MKH!<YK66N`_<KMKNM_S:ZW/0OJOC=2Z9F]6MZA2&U=3RW9E9H%]CF%_M]"UI
MQJMWL_PM?Z-="<W&<TM<RYS7"'`X]QD<:_H43\UJZ+=*NHR>F8>1CF:;J*GU
MG^26-<Q6RN9P,?*Z(XX_2-V1TMSG.KP<FJ^M]&XE[F8N6RB[=1[O9C9%7Z/_
M`$ZL969UW+9Z%31TQC]+,@5W9-S0?^X]?V>G';9^[;;;;Z?^@0KKW5;F?4MC
MK/K-];<VO7%LRZZ&.[&VAMGVD?V?5K6U5AXF>WK&%F5"[&R,DLMJ=PX&C%T_
M>W?G,>WZ"ETMG3.E8->#ATWLHJ!B:+W.<22ZRRQ[J=[[;'^][T'I63F4W]0?
MG4&NO)R#=C&IEUAV>G50UE[/0;LN_0^I[/9^D_X-$ZDE3E=!S<CZM=3K^J?5
MKG68=W_(.?;^>P&/V;?9]'[31]&C_2?S;/3_`%:I:N/_`.)C,^&=/_;N2GZ]
MA]+Z[TU^!EUWACB'U6MHN%E5K9]+(I/I;FV5N_Z'L0>G4Y>-]3[<7.>ZW+HQ
MKQ?<YKV^HYWJO]:;F5/>ZQKM]GY^_P#G/>B-2#U,@IPO\77UAZ3@_4W`Q\FU
M[;6>L7-;3<\";K7:.II>QWM*ZGH/U@PNNUY5^"7.IQL@XP>YKF%Q8RJVQWIV
MAEE>U]_I^_\`<61_BNG_`)B].'G?_P"?[ET]5%-5EUE;`UV0\67$?G/#*Z=[
MO^M4U,3959\U!__2],R\3'S<:W$RJA=CWL-=M3OHN:>=W_F/T%@8'1OK-T(-
MP^EY&/U+I-8/V>C/?93?2/S*&9F/5DMR*&?F>M1^C_FO\&NF21%UX*<9N%U_
M.M)ZK=3B8;7!S</`<]S[(+7M^T]0M9C6>EO;[J<;&Q_4_P`+D>CZE3]*BJUE
MU[WN)8]P-0+B8&T;_:?H?I-Z.DFFK%J'5I9F/FV6[J+2QFQHVAT218U[_P"K
M^B]B/ELNLQ;:Z'%EKFD5N$B#V.Y&230(^JCYIUT8U![:VA^K@/<>56P*,REK
MVY-A?N,M.XN+?Y'"MI)4/3J?#Q5KJUKJ\MV3396Z*F2+&3HX/'N=_7J<UGI_
MVT^93?=4UE+S6[>TO<"0=L_I-I_>V_05A)(U4M>JM=&`8X4>F'.<X-VASOI$
MQ])Q_>4,-E]>-6R]Q?:UH#W$S+H$N1DD=.+Z*Z-.BC+9D[['[JAZNFXF=[V/
MH]D?X*L.8BY%5MEE#F.+6LL)M`<6RW;8W;[?I?I75O1TDT"-&B?F"3:',KNL
MQGLH);88VNG;$$?G)\IEUF/8RA_IVN:0Q\<'LBI)VFODA'2'-8`06DF2TDNC
MX.*SNHX_5W=/S<?#;7=;DA[*/M%CF-K%C2PNL>RNUSV5N]S*VM_ZXM5)(5Z:
M/DKN\G]5NE?6SZO=$HZ.[%P,P8YL++VY=M6CWNNA[#@7>_?8_P!ZU^GU]?LZ
MB_)ZFW'QL1E0KQL7&M?=[W&;;K[+:,7\UC&4;&?GVK523S=H?__9_^T4ME!H
M;W1O<VAO<"`S+C``.$))300E```````0`````````````````````#A"24T#
M[0``````$`!@`````0`!`&`````!``$X0DE-!"8```````X`````````````
M/X```#A"24T$#0``````!````!XX0DE-!!D```````0````>.$))30/S````
M```)```````````!`#A"24T$"@```````0``.$))32<0```````*``$`````
M`````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`
M!@```````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"
M24T#^```````<```_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@`````_____________________________P/H```X0DE-!`@``````!``
M```!```"0````D``````.$))300>```````$`````#A"24T$&@`````#10``
M``8``````````````$4```"Z````"`!I`&T`80!G`&4`,``P`#(````!````
M``````````````````````$``````````````+H```!%````````````````
M``````$`````````````````````````$`````$```````!N=6QL`````@``
M``9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````
M``````!,969T;&]N9P``````````0G1O;6QO;F<```!%`````%)G:'1L;VYG
M````N@````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2
M````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I
M9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4
M>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P``
M``$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`
M`````````$)T;VUL;VYG````10````!29VAT;&]N9P```+H````#=7)L5$58
M5`````$```````!N=6QL5$585`````$```````!-<V=E5$585`````$`````
M``9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(
M8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E
M2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI
M8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````1
M15-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````
M``````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``
M```````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_``
M```````X0DE-!!$```````$!`#A"24T$%```````!`````$X0DE-!`P`````
M#O8````!````H````#L```'@``!NH```#MH`&``!_]C_X``02D9)1@`!`@$`
M2`!(``#_[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)
M"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,
M#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`#L`H`,!
M(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)
M"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%
M`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!
M``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/4TDDDE*22224I)
M)*0DI229SVM:7.(:T"23H%FV=9;<\U=-J?FV`P7MTJ:?Y5Y]O^8F3R1CN?L]
M4O\`$2(DND2!SP.5G7=9H%IHPVNS<D<UU:M$Z>^WZ#5RW6?K3B,R/L-EK^M=
M2)AO1^FB:P?SFY.2&O\`H_X3;^EJ_P!&J5W2NM=09Z?UER1T_",%GU>Z80US
MA_YL,J7?N,<_?9?O_P`%Z#TR1F(F4B,./]Z9]<O^I_HKA$70N<NP^5Z/$^M-
MMEML"C/IJ/Z88%K;;*/Y-]0/Z3_CF?HULX74\'J%9=B7-L('N9P\?UJS[EYY
ME=%Z&ZQ@QZ#T>[&:!BY_3R]MM6CF_IFN=^O-]WZ6S?1E_P#"J=^5UCIP&5U[
M%'5<`:U_6'I4-O8!N]V;0W8WV>S?ZC*O2_TUUBCQ9/<XO8R>Y1UQ9AP9?\'@
M_17SA5<<>#^M'U1_Q'TR4ERO1^OY61C_`&GI^17U_!9&YU7LRJY_T]#]KOS?
MSF^];>!UKI^>=M-NVYNCZ+)98T_NNK?"ECGCQ<,@<>3]R?I_YWR2_P`%C,#5
MBI#N&^DEN$QW24JU22222E))))*?_]#U-*?)9_7NMX?0NE7]3S#^BI`VL;])
M[W>VJFO^78__`-*+-P>B9W4ZVYGUDNN-]S0YO3*+GTX^.T^YM3_LSZGYF0W_
M``]V19:SU/YFOTTJTM3T4_BE*Y3ZP_5_JN!TV_+^JV?E8V16V78;['9-5C!K
M:VEF=]I?C9&S^:^SN_,]'T_?ZE?39.15BX]V3<[;3CL=;8[P:P;W'\$2%))\
MD+(^T[#]E#/4/>S=`_LL^FN4^JV5U##^LG4^C]3>][\^JOJ^*RPSL]7]'G8S
M7%WT,>[9337_`*.I;WUDHKMZ#U`/!&W'ML:6DM<'L:^VNQCZRUS7->-R$HV:
M[J!ZL3T=]P-G4KCF/&K*-:Z`1P-C9_SK%A9OU8^M/6[/LW5NI4]-Z09:<'I0
M<'/:2X;+LF]C/S'>[V>A9_W&1/JST/&ZG]4NG9#[;Z,Z['#_`+;5=:VT6._P
MV[U/TG_%V_HEG8?UMZGU+ZN=&9==]DS>IY_[,RLZIH'M:7>K;C<UU967MKJK
M?Z7ILM?=9577^C0AC$"3`:WZI2UE]J3(G?['HL3ZM4](Q?L?U?JIZ?4X?I;H
M<Z]Y_EW.]_YWY[O^*])`'U9S.?6KDR3HXDD_G.=])6LGZMT%U%N#?D8=^/=7
M87C(N>VUC'AUE&8RVQ_VEE[-V[?^E_X1-C_53!#\FS)NRK;,G(MO+6Y614Q@
MM>;&U5TX]U53=K2W?[??8H\G+XLAN9E+Z_L70RRAI&@T;?JGGN>7MOJ\M'"(
M"GA_5WK.!=ZN)EU5N/TFD.VOC\VQG_?OYW_A%0^JW3ZNHYG7:\V_,N9@]1LQ
M\5IS<H!E30W;6W;D-_Z2VZ<7`^K./U/J%M]IPS&2_P!:Q]SV>G6VIU;+<A]E
MUN[8STF/L_G+%%_H_EXR,@)"7A(A<>8R$4:(<SJ?U!P<RUO4>GV'H?6P).5@
M$BMSCSZM`]/<RS\_^:W_`.%]96<+HO6LAGI_6<8>6ZMH%6?B;ZL@G_A6;&5^
M[_@G^G_P"ET?%SNN8=75>LV6TUY;?5Q>FX]CJJZZ7^^G[0^@UY&7E.K_`$EW
MJO\`0_T>/6K5_P!76,87])R;^G9+=:W-L?943V&1B9#[*;:_])M].[_AE:E&
M,H\$ZGT]7JW_`*S$"0;&C+&PNL8;]E66W+Q>`W)!%C1X-OJ^E_UQ:HTF?GY+
M&^KO6!US`OKRZVTYV)8_#ZEC-)+6VL]CS4[Z?V>[^<I=_8]3]&N?QL_(^J/6
MLBG(M?;]5LC)%%5UKW6.PKS739MLNMW/;A7NMV-WO_1_]N?:&X\0C8!.GZ)/
M$/\`!XDRE=$O<[D\^147,;8QU;QN:\%KAXAWTES5'2<,_5',I'J#:<NQEOJO
M-K7UOOKIM9>YSK=]3*V-K3P+KS0]/\DEPOU!Z)T_J_U4P>H=2%V3F6^L++G9
M%\G;=;6SZ-S6^UC6KI>E=!HZ3FY%F'9;]ER:V#[/;;9:&/87DNI^T/L=7ZK;
M?TGN_P`&D0+4_P#_T=KZ]/=E_6KZJ](<?U=V4<JYAU#C46>GN']1MS/^NKN0
M!_KXKA?\8U5F#G]!^LP!./TO*#,S:)(JM<SW\?1]EM7]>VI=PQS7`.8=S'"6
MN!D$'4$?R43\L>RNK)9'UC-UM6-TW&K9=;FW-WU6/=6PT4$9.3ZEC*[_`-';
MLKQ7_H_^U*URL1K\O_G!;EY53AAU4G&Q',9;8_<7^IEV/8RG8QE^RAM7IV_X
M'_MM!1<+ZV/ZK@]0Z3]:<K%HQZNE7BK+LIO=<3CY1^SW>HU^-B_S.[]'[O\`
M#+J.O:]!ZE&H^R7Z_P#6[%5^L#:^J=$S>FUTV66Y=+Z6"RFYC0]P/I6.?Z+]
MK:K?TBHT_MH?5-W2<JD6]3&*<-MC!?Z+Y8:&Y%EK\;>S;7^DM]G\ZCO1[%2#
MZJ8G5LKZG=+IJZ@W$HLQV`NIH_6`P\MJR+;[:66?\+]D_L+4R/J?T&_ZOM^K
MSL?9T^L?HMI_25OESADU6NW?K&][_?\`R]EGZ+]&A_59M_2NA8G3<^MS;\1@
MJ+J:[K*WM:3LL:YU%;O>W\QZEU2SJ3\_"S>E6%HQVVLR,6^C(#+FV&HLFRNE
M[J'T^C8ZN[T[/_!7I&[/FIQ3U'ZR_4ZZEO6;_P!L_5ZQ[:1U$B,K&+R&U_;.
M?7J_?L]__&?S6-;VS9D_'1<UU:O,Z[CU]/ZAC?9>G/LKLS&L;?=9:*GMO9C5
M[<:GT:[+:V>I<YWJ;/8RK_"+<=U"F"0R\GL!1=_U7I(2UKHIYWZD?\H?6C_T
M[6_D:C?XR<:_)^I/4ZZ`7.:UEK@/W*[:[K?\VNMST+ZKXW4NF9O5K>H4AM74
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MIU.7C?4^W%SGNMRZ,:\7W.:]OJ.=ZK_6FYE3WNL:[?9^?O\`YSWHC4@]3(*<
M+_%U]8>DX/U-P,?)M>VUGK%S6TW/`FZUVCJ:7L=[2NIZ#]8,+KM>5?@ESJ<;
M(.,'N:YA<6,JML=Z=H997M??Z?O_`'%D?XKI_P"8O3AYW_\`G^Y=/51359=9
M6P-=D/%EQ'YSPRNG>[_K5-3$V56?-0?_TO3,O$Q\W&MQ,JH78][#7;4[Z+FG
MG=_YC]!8&!T;ZS="#</I>1C]2Z36#]GHSWV4WTC\RAF9CU9+<BAGYGK4?H_Y
MK_!KIDD1=>"G&;A=?SK2>JW4XF&UP<W#P'/<^R"U[?M/4+68UGI;V^ZG&QL?
MU/\`"Y'H^I4_2HJM9=>][B6/<#4"XF!M&_VGZ'Z3>CI)IJQ:AU:69CYMENZB
MTL9L:-H=$D6->_\`J_HO8CY;+K,6VNAQ9:YI%;A(@]CN1DDT"/JH^:==&-0>
MVMH?JX#W'E5L"C,I:]N387[C+3N+BW^1PK:25#TZGP\5:ZM:ZO+=DTV5NBID
MBQDZ.#Q[G?UZG-9Z?]M/F4WW5-92\UNWM+W`D';/Z3:?WMOT%822-5+7JK71
M@&.%'IASG.#=H<[Z1,?2<?WE##9?7C5LO<7VM:`]Q,RZ!+D9)'3B^BNC3HHR
MV9.^Q^ZH>KIN)G>]CZ/9'^"K#F(N15;990YCBUK+";0'%LMVV-V^WZ7Z5U;T
M=)-`C1HGY@DVAS*[K,9[*"6V&-KIVQ!'YR?*9=9CV,H?Z=KFD,?'![(J2=IK
MY(1TAS6`$%I)DM)+H^#BL[J./U=W3\W'PVUW6Y(>RC[18YC:Q8TL+K'LKM<]
ME;O<RMK?^N+522%>FCY*[O)_5;I7UL^KW1*.CNQ<#,&.;"R]N7;5H][KH>PX
M%WOWV/\`>M?I]?7[.HOR>IMQ\;$94*\;%QK7W>]QFVZ^RVC%_-8QE&QGY]JU
M4D\W:'__V3A"24T$(0``````4P````$!````#P!!`&0`;P!B`&4`(`!0`&@`
M;P!T`&\`<P!H`&\`<````!(`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'``(`!#`%,````!`#A"24T$!@``````!P`&`````0$`_^$8`FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED
M/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/'@Z>&UP;65T82!X;6QN
M<SIX/2=A9&]B93IN<SIM971A+R<@>#IX;7!T:STG6$U0('1O;VQK:70@,RXP
M+3(X+"!F<F%M97=O<FL@,2XV)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P
M.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN
M<SII6#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA-&(X83DW."TP,#%F+3$Q93$M
M8C=C8BUE,#0S,S$T8F8R8S$G"B`@>&UL;G,Z97AI9CTG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]E>&EF+S$N,"\G/@H@(#QE>&EF.D-O;&]R4W!A8V4^-#(Y-#DV
M-S(Y-3PO97AI9CI#;VQO<E-P86-E/@H@(#QE>&EF.E!I>&5L6$1I;65N<VEO
M;CXQ.#8\+V5X:68Z4&EX96Q81&EM96YS:6]N/@H@(#QE>&EF.E!I>&5L641I
M;65N<VEO;CXV.3PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`\+W)D9CI$97-C
M<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA
M-&(X83DW."TP,#%F+3$Q93$M8C=C8BUE,#0S,S$T8F8R8S$G"B`@>&UL;G,Z
M<&1F/2=H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O)SX*(#PO<F1F.D1E
M<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED
M.F$T8CAA.3<X+3`P,68M,3%E,2UB-V-B+64P-#,S,31B9C)C,2<*("!X;6QN
M<SIP:&]T;W-H;W`])VAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\G/@H@(#QP:&]T;W-H;W`Z2&ES=&]R>3X\+W!H;W1O<VAO<#I(:7-T;W)Y
M/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70])W5U:60Z831B.&$Y-S@M,#`Q9BTQ,64Q+6(W8V(M93`T,S,Q-&)F
M,F,Q)PH@('AM;&YS.G1I9F8])VAT='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q
M+C`O)SX*("`\=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N
M/@H@(#QT:69F.EA297-O;'5T:6]N/CDV+S$\+W1I9F8Z6%)E<V]L=71I;VX^
M"B`@/'1I9F8Z65)E<V]L=71I;VX^.38O,3PO=&EF9CI94F5S;VQU=&EO;CX*
M("`\=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET
M/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70])W5U:60Z831B.&$Y-S@M,#`Q9BTQ,64Q+6(W8V(M93`T,S,Q-&)F
M,F,Q)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+R<^"B`@/'AA<#I#<F5A=&5$871E/C(P,3$M,3`M,C94,34Z,3,Z,C$M,#@Z
M,#`\+WAA<#I#<F5A=&5$871E/@H@(#QX87`Z36]D:69Y1&%T93XR,#$Q+3$P
M+3(V5#$U.C$S.C(Q+3`X.C`P/"]X87`Z36]D:69Y1&%T93X*("`\>&%P.DUE
M=&%D871A1&%T93XR,#$Q+3$P+3(V5#$U.C$S.C(Q+3`X.C`P/"]X87`Z365T
M861A=&%$871E/@H@(#QX87`Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P
M($-3(%=I;F1O=W,\+WAA<#I#<F5A=&]R5&]O;#X*(#PO<F1F.D1E<V-R:7!T
M:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.F$T8CAA
M.3<X+3`P,68M,3%E,2UB-V-B+64P-#,S,31B9C)C,2<*("!X;6QN<SIX87!-
M33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^"B`@/'AA<$U-
M.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.F$T8CAA.3<W+3`P
M,68M,3%E,2UB-V-B+64P-#,S,31B9C)C,3PO>&%P34TZ1&]C=6UE;G1)1#X*
M(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2=U=6ED.F$T8CAA.3<X+3`P,68M,3%E,2UB-V-B+64P-#,S,31B9C)C
M,2<*("!X;6QN<SID8STG:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\G/@H@(#QD8SIF;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R;6%T/@H@/"]R
M9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX;7!M971A/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X
M<&%C:V5T(&5N9#TG=R<_/O_N``Y!9&]B90!D0`````'_VP"$``("`@("`@("
M`@(#`@("`P0#`@(#!`4$!`0$!`4&!04%!04%!@8'!P@'!P8)"0H*"0D,#`P,
M#`P,#`P,#`P,#`P!`P,#!00%"08&"0T*"0H-#PX.#@X/#PP,#`P,#P\,#`P,
M#`P/#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$4`N@,!$0`"
M$0$#$0'_W0`$`!C_Q`&B````!P$!`0$!```````````$!0,"!@$`!P@)"@L!
M``("`P$!`0$!``````````$``@,$!08'"`D*"Q```@$#`P($`@8'`P0"!@)S
M`0(#$00`!2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O`D<H+Q)4,T4Y*B
MLF-SPC5$)Y.CLS875&1TP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5U
MA96EM<75Y?5F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I
M.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ$0`"`@$"`P4%!`4&!`@#`VT!
M``(1`P0A$C%!!5$382(&<8&1,J&Q\!3!T>$C0A528G+Q,R0T0X(6DE,EHF.R
MP@=STC7B1(,75),("0H8&28V11HG9'15-_*CL\,H*=/C\X24I+3$U.3T976%
ME:6UQ=7E]4969G:&EJ:VQM;F]D=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@Y
M25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`/OIBKL5
M=BKL5=BKL5=BKL5:VIMD.,P'J9<36U/'!QF8]#'Q$LO]0L=.M'OK^\BLK2'>
M:ZF;A&GWY7GG/!'BE/;W,\0R9S6,/"M=_/&*8W=A^7^D3>:+NUC]2;5'/HZ;
M`*;2S3'HGC]C.9U'M3&!H8^/X\/^]=KC[.A'_&95]OW(#RW_`,Y%:2]W'H?Y
MC:7<?E]YA'0WJ<[&6@_O8I@/[LGO2G^7FM[,]O=)EGP:V/@Y+V%RR7\8QH-F
M;L;)+^Y-_CS+Z%BO;._LTO+*YCN[26CQ743<T>OA3.[!&>`E_"=QYNCRXQA-
M9_Q\DSW^>72B:V-+P!V_;(CBCSW^Q/#%O"AV*NQ5V*NQ5V*NQ5V*O__0^^F*
MNQ5V*NQ5V*NQ5V*NQ5)M6US2]#LGOM6U*WTVTC_W?.PC'XYKM3VC#00XM1+[
M/^)!;L>,DU3Q"_\`S@UCS"\MC^6GER763'M+YDOE^KV,)I_>5(J<Y[/V_P#G
M_3H^?X_G`.SQ]G@[R-?C[7Y]_F[_`,Y8?ESY?\P1>4K.]U;_`)RD_.2[E^KZ
M;^67DMY9=)BNAMZ<UY!$2:T^Q;15\<V_97L'JLOK[3GMSY#_`'DA37F[;Q`5
MI8\/X_I!YEY@_)K\]OSGM8[K_G+/S\GY8>1*?6=(_P"<7ORX>.VE$?6$ZK+^
M_AC_`.,DOUB3_C'FTUOM1H/9>/#IH<9`J[D/O$F.F[.S:\WD/7R_04K\O^1?
M^<@?RETLK^0?F"+_`)R:_*"PI+J7_./OGA?^=@TJ*F_Z*E!I)0#^\L91N?\`
M><G*--[2]A^VT##41\&?*KR3^T"%?/9.?3ZWL\W'E_F_M^UZO^2/_.27Y?>;
MM9DT3\M?.VI_D7^9\5P8]7_(S\PG].WENJ&L=I=3TCD]HW].7VSF.U/^!SG[
M(D<FBEPQ[Z!^R<Y.3INVM%*AK8WY[[?Z4/O/2O\`G(&;1+J+0_S=\K77DG4'
M/IQ:Y&#+ID]1N0=Z?(<\P]%[6?ESP]I>@_/_`*9Q7+V0>'B@01^/-]$:9K&F
M:U81ZEI.HV^IV4W]U=6SB2,_2*C.PTW:6/6X^+1GB'?R_P!T`Z3+I91E2=YL
M6+L5=BKL5=BKL5=BKL5?_]'[Z8>2NR)R*UDKME;>`RX5MV(G;%V)G2L5U_S/
MH/E>R^N:YJEOI\!!]'U)*22'PCBZR?1FLU.N_)PO4&_L_P!S;9BQ'42>1R?F
M-YV\Z,]I^7'EE[73_L?XMUE?3A/_`!BAZG-#E[;U.KVT(KY?[\.WQ:'#AWR2
M^&[XI_.7_G)?\@/R?UI=%\P:[JG_`#DS^=LDGU:S_+?RO_I$5O==?2EE@_=1
M?\8_WDG_`!5FW[-]B)99B><_CX2<7/VL3'A`H?CR8+-^3O\`SEQ_SE5IPU3_
M`)R.\Y0_\XL?\X^BK1?D_P"6S]7U.[M14^E=^%1_OZN__'MG79]9HNQX#@(-
M#F+_`./?8ZLRG-ZQY0TK\I_R,T:3RG_SCUY(M?*$$T?IZQYZG3ZQK>I?*ZF_
M>_1V_P!]QYY5V_[=Y^U!P\?V#_B0]7V?V-CQFY'X;_K8[<N\R7$\\CR22^K)
M--)_>R9YWX.24K,_L>EK#`5?WO+[.[NM-N;>]TZ[FLM0M9/4M+N!_3ECESB,
M>LEIIB0Z.QRQP9(U?WLU\V:=^1__`#D58P>7O^<D/)4$VN11_5M'_-_1T^HZ
MO:=!_I4L((D^7[R+_BO/9_9/_@JY-!$1/X_V!>*[3["A,\4/E^"QF7R-_P`Y
MC_\`.*>DK)Y*U&U_YS4_YQL:/U1Y/U0&YUNRLJ;"U/[^4T'^^O5C_P"*H\]D
MF>R_:/$1E%&7G+K[N%Y/#FEI3?X_2S[\DOSF_(W\Y;Y5_([\R;S\EOS6/_'4
M_)_S23'ZDU:2QP+-RBN.Y_=F0C_?<>>>:_V!U?9V0S[-D0/<#_NY%WV'MHYH
M\,P#^/<^NX/SF\V^2Y8],_.+R=<:?$:1P><-&7ZS8/\`\9:;C]?_`!7FKC[3
MZCLTB/;$.$GK8/V8@5R]FXLPO&;\MWT#H7F?0?-.G1:CY>U:VUBPDI^^M9!*
M-Q^W3['TYVN@[3TW:./BT_K'QC_N@'39H_ECR9/FTY,79'AM78.:V['DMNPC
M(KJY+B5__]+[Z8(FU>%_F%^?_P"7_P"7OF+3_(\PU;SC^8VKP?6M-_+?RI9R
M:MK<EM6GUF6&']U;6_\`Q;<RQQ^^9$=/Q"^B6+:Q_P`Y#Z_Y4M/TKYS_`.<>
M/S,T+0E3G=:W86^E:]]5C'62[M-'U*YN_P#D5%)ED,'%R(_'S8<3,/R@_P"<
M@ORB_/B'5[K\I_.,'G&T\O):G6+JWAFBCAFO?4]**03Q0_O/W1VS'U&(QYKQ
M)U^<WYI>7_R5_+3S=^:'F.UNK[2/*EH+B>QL4$ES<.91%%%$":<S)(!AP8^(
MTR3/\L?/V@?FG^7_`)/_`#'\K,9-!\ZZ7;:KIS.`)4CN(@WIRT_W9$?W9]\&
M;'1I+&_SF_,(?E/Y`\Q?F/=>2KWSC8^4[.74M>L],:U%['8VT9EFFB%VT(D]
M(;TK7*\6GC/:7J^Q,L_A\GE_D[_G(_7?.WY9>7_S9\O_`)&>;;_R+YALAJFG
M1Z=<:/=:F;&A_>C3Q>B60GM''5_;,F.EPPVNC\6J0R9SM^AZ1^5OGO\`*+\T
M/*-K^9'Y;76DWFA2+*)M5BM8[.XL98?]ZX;J.:-9;>6+_=B24^[,?5PUG'5G
M["RD8CFD>F_G:GG?2G\Q_EW^6_F/\R?)T#N+/S59_HRSM=2]&@,NDC4[RVEN
MHZ]):"*3_=4DF63T6*4:SG?X_H1CU,0\]U+_`)RD\J)Y`T'\P]$_*;SEYGCU
MCSW)Y`E\D6VFQ1^9+>_MS,9O]Q\TH_N9+5J@RI_OS&.@Q0-<73N-?CX,OS>3
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MX0N0X1[V@98YMDJU3S[/HS/K?G#_`)QW\QV-E#)ZTNMZ=;Z/KUS#_P`6RVNF
MWD]X3_QBBDR4,<Y2K'.OL1MB>F>3/.GDO\RO+UGYF\G>8+'S=Y>U$$PZE9R<
MXQ("#)'*`?W<D?>-P'0[$=LQ,L<^`\,(;=]C].[=B&7%N3]SPW\[?^<D_+W_
M`#CCJOEB;S[Y"UNP_+[S3J5MI5Q^:NFI:W&F:;<W&X_2$0F^M11^_I?+?,O2
MZ&$]X;SZCE^FFO-F$_JW?4-I>6FI6EO>V5S%>65[''/:W4+^I')'-_=212#;
M<;YC9-DO/OS:\_77Y7^1M>\^IY3U/SI9^6+.74=5TK2);>.]^JVT9FFDB$\L
M`DH/V*[YD8(<>UI><_FQ^?FI_E#^5#?F[YG_`"H\PW&AZ;:QWOFS0]/NK"XU
M#2HY9A$OJ1^L(9:<_P![Z<IX#)X,(D:O=JXF'_EG_P`Y2>:_S:\D:%^8OD#_
M`)QQ\Z:UY/\`,<<TNDZC)JGENU,GH32P2_NIM3$NTL3CIAS8!':T<3*?*7_.
M0VKZQ^:VD_E-YM_(_P`[?EIJ^N:9?:IHWF'6?T7=:1<Q6'I>M%%=Z;>W(]7]
MZGP9&6G`%C?\>]N?3U<HI#__T_JS_P`Y:_GW:_\`.-OY'>;_`,RC'!<:[%#'
MIWDO3Y-H[C6+ZL5K6M!Z<7Q2R_\`%:'+=%A\0L9L8_YP\_)>X_++\L+/S3YN
MGFU_\Z/S9CA\U?F]YPO6$E]=ZA>1^K%:F4C^[LXY/2BC'[L?'3KEVMR<6W0;
M+!]A',.,V3P_\N/R2\L?EAY__-[SAY6M;;3+/\V;S3-6UC2[:/TXX]3LHIH;
MN44%#Z_J))_QDYY>9V$A1\_V-CY[_,3R=^7>HV\=]H.E:7J?FKSA:2)6*2.>
M*71].@EZ?WWUFYD_YX9+'(P-CFTSW?)/_/N_5;[R7IWYT_\`.+'F*\:76O\`
MG';SG=VV@>HX]27R[JTLL]G+],GJ2?[-,RNT(B8$AU7'L^L/^<HO_6;/^<@/
M_-=^9_\`NES9BZ'?4CWLYL$_YP3-/^</_P#G'X^'E2U_Y.29;VCB_P`)/E7W
M!<3\[_RP\J>=O.WDS_GZ+<_D\MS)Y3_,'7]4L_RT6P!,6I7T`O/TM^CR/M^O
M'(D8,?7DF;')&$>"^?7Y?K^YJ$7WQ_SA5^?OY8_G'^2_D'0_*&J6MAYJ\B>6
M].T+S9Y#9Q#?:;<Z?;16DP^J['TJQ'TI.E/IS4ZK'*R6T/JV+RWH-O=F\M],
MMXK@ZC)JIF1=S?30_5);FO\`OPQ?N_EE)G45QOE__G/W_P!8Y_/W_P`!L_\`
M45%F1V6>++'X_<N1ZE_SC;_ZSK^0_P#X`'ES_NEPY#5G_"#[TXWB?_.</YTW
M?_.-?_../G3S;Y-BCL/.'FJ_CT7RM=I_NO5-5,GJW5/YXHHI)?\`C)E^ATHS
M:C?\;(R/7?\`G&S\IM+_`"8_*#RIY/L(WFU:2TCU3SKK4Y]6YU+7[Z,3:C?W
M,I_>2R32]R:\.`RC6:CBFR>_YB9AQ15^7GYB:Y_T+%_SG1^5%[Y?!L_R]_YR
MZ$^E>?\`RXAXVW^)K*6*&TU>*(#]W/-]:ABE-/WGQUJ<W>(?F,!/4<FC-]3[
M`_YR1\H^7O/_`.7^E^1_-6GIJOEGS9YL\NZ7K=@YIZUO-J$7?MOFMT4OR^0D
M<VS-]+XP_(CSKYI_YPY_-73O^<2OSJU>;5?RL\SRR/\`\XR_FM>FD?HM)0Z#
M>2$_NY(2XCB\#_Q5)$(]IK(#M*'YH?6.?PV\ARKIR8Q%;/O_`/.RO_*G?S6'
M;_"&L_\`4)-FIQY)``]6X&GEG_.8W_K(OY^?^`'JG_4*<R^S-]4/C]Q:LG)@
M?_/M[_UBW\D?^8+4_P#NJW>'M6/^$_#]",3[.NM.L+V]TN^N8$FO-&DDET^6
MO]WZT9AE_P"2<F:_Q&U-/HQ\17__U.S?\_:+J34)_P#G%/R9.]=#\Q^>Y)=8
MB_W6X@^J0[_\\[I\WG8F/BA(^[]+#(_8M5X*J)LD>:(SXITF"_Z</ALG8*5\
MF>4_*_G?\P/,7YA_FEY>_-?4O)FF^8=8DT'0]-L-.TJ]CDTWRW++I\4OJWMI
M<2CU;KZS+_L\R<@X2`6F'J?)_F[2->_YQJ_YSF_)?\SM?\Y7GFS0/^<E-/NO
MRZ\Z:W=VEC9\-4M_2_0_JQV<,$7:&,'K\+YL(@9<1`'T_P!OV[LL@X7W/_SE
M%_ZS7^?_`/YKOS-_W2YLUV@VU(][+(^;/^<//R>\B><?^<1?R1'F:UUC5[/6
M/*L$FHZ')KNLC3+BLLFTNGQ7@@,?_%?I^GF3K]01J?QW+C?=6DZ7Y<\H:-I>
MB:+I^G>5O+]B([/2-)LXH[.VMQ_NJ*&&(",=.@S7<4H_4V&+XS_/_P#YP3_+
MG\VM8N/S)\@W=[^27YZ02&]TC\RO*[O9M-?4!$NH10T]7_C(.$GOF?I^T1':
M7J#7)&?\X3?G+^9GYF^5OS%\B?G1!`_YI?D9YLF\H>9];M%*0ZFL$8,%UMQ'
MJ&CU['X).^.NTP@`1R(7&R/_`)S\_P#6.?S^_P#`</\`U%19C=DFLH^/W+D>
MI?\`.-G_`*SO^0__`)K_`,N_]TN'(ZTUJ?BL'R__`,_./RPU_P#,K_G%G6[G
MRU:O?ZO^6VLV/F\:?#\<D]K8QS0W?O\`N8KEY?\`89LNQ\XCJ:*,C[*_*7SU
MI'YG_EEY&\_Z#<1W>F>;-&LM1ADC-0/7C_>1=!_=2<T_V.:O58JF?>V/1>^,
M_I0_++_G*/19_P`Y?^<Y?^<0_P`M-`K=/^4)N_S%_,"ZC%?J%B+JTEM!+WC]
M::Q2/_9IFVT<O!P2/>X^7ZGWG^;NVE^2/;SYY7_[J$6:O#ZY'R!;<WTL=_YR
M!_(;R5_SD7^6>M?ESYUM6C2[I<Z%K]O'_I>E:G#40WUJ33>+P_W8A,9ZY/2Z
MPZ2?$/I9D/AW\M_SY\\:?Y*_.G_G$S_G(R9K7\\/R[\CZP/*_F9B?2\X:##I
M\QAO[:4DF6X$?][W?_C(DN;++HN&0U0^@G]G??/RV:C)]>_\YC?^LB?GW_X`
M&J?]0IS$[*_QL?'[BG)R?+G_`#@7^9/G30_^<2?R@TO2OR)\Y>;K&ULM0]'S
M%IMYY<CM+NNJ7?\`=?7=8MIMO[O]Y$.F97:4`=2=_P`4C$^FOR6_.;\POS)_
M-;\W_*WG'\K=8_*K3_(VD>7)-"T/79[2XNK[]*2ZJ)KX364L\/IUM4C_`'<T
MGV<P-1IQ``@VW/JO,"D/_]7U?_S]8_*_6?-WY`Z+^8_EJ)[C7/R4U^+S%*J5
MYBPF_<W4@%/]TR>C*?\`BM'S9]BY1*XGK^ACDY/O7\G/S&T;\WORO\C?F9H4
ML=QI_G+2+740$W].5H_W\/3[<,H:,_ZN86KT_AY#Y?@+!Z?3,02E+HSNGF'Y
MM:CYUTSR3K'_`"KZWMI/.=_!+9Z!=WT5U+;VES-%)Z5S-%9PW$T@BIN`,R\$
M(?Q%%6PO\I-4?R;^6GD?RAKVC:JNK^5]&LM*U*33M)U6XMKB:"(0RW,4LUG!
M)2:2LG2N&>,`<VK'ED7@G_.:7Y>^8?\`G([\N-&\D^0[:;R_Y@T'S%8>9M'\
MWZQI6LQ_4+JQ]7^ZCATV<F3][E_9>KABF3:Y)29M^95W^:7YA?\`.//FC\NY
M]$L[?\R_.OERZ\N:YJHL->&CQ"^M/0O+Z'_<;ZW^[']*/_DIC@CCQZCCZ)X;
M5O\`G%ZP\R?D]^2WDK\J_/>GS7FI>1+`:79ZUH6EZQ);7=J)9?1D,<UE`8Y/
M'!J1'+GXQ^-EX>%EWYX6<GYK?E]?>4/+^O\`FC\N];FU31M3TSSA:>7+^YN;
M&72M0M=1$L4)A`D/^C4RK32C';FB<I!*[/SY^?5II[:7?:-Y=UO4XXQ'!YO&
ME>9[&%R/]W2Z2-,G._\`ON.[_P">F69(8XV05ADEU5?R4\L>6_R?T/S';<O,
MGFCS9YZ\P7WFO\P?.%QY=U"WEU/5[]AZTD4/H?NHH1QCBB_W7&OTY#52CDWZ
M(EDD),9_YRLTSS+^<_Y+><ORK\A:=+97WGFS&GZAK&NZ5K445I;>K'+-Z<4&
MG3^K)2/88=-.%[GDSU$Y<.P9?^1.H:[Y%_*?R)Y&\]Z3=2ZYY)T.PT$:AH6E
M:Q<VMU%80Q013#U[*"6.OI_W9R&KC`29\WL#^>](=7232O,,D<G^ZOT#J?\`
MU0R$\8,4U3YB\O>1;G\G]2UBX_(2^U'R]Y4UZ]EU#4?R?\P^7-8N=#@O9R99
M9M)FM(1-IOK`U,7[R+PB3+XG'(4>?>'$!E%FU_YX_.O6(/J-AI.C>1I)5*3>
M8/T7YC\P21U_W9%:?HVPBY^TLN/Y;%C-W?X][<)S+?Y2^4/(OY3?XAU.RM?-
MWF;SQYVO!J/Y@_F'K&BZA-JVM76_I>K+!9+%''"*1PV\?IQ11]O$YA8K9ECB
M@OSOU/SUYKM/(]K^6FE".30O-6C^8-?N/,.FZ[;K/::7="8VD/HZ9/\`O)J?
MWG^Z\&@C`$V5F'M]MY^T]H+=KO1?,%O<%*S0IHFJ2QQOW_>_4\QCBC#9L(?(
MW_.7?Y'^3_\`G);RC8-9VVN>6OS0\F/];\@><TT+5(Y(FY?O+&ZFA@!^KS]_
M]]_W@[UV.AR#!*SR+60]'_YRXOX=2_YQ"_/JZA@NK:,^2-43TKJVDMI!^Y/^
MZ9J'*>R)WJQ\?N+#40H,._Y]O_\`K%OY)?\`,%J?_=5N\M[7_P`:^'Z%P/M1
M+&SCO9+]+9/KTMO'!/<\1ZCQ0&0Q1_1ZCYK.&FU'9*E?_];[P:C8V&JV5UIN
MHVT5]87\$EM?6,R^I%-%,#%+')&1NA'7(#+^6D*]_P".:)A^>_E7\AOSS_YQ
M,\PZV_\`SC=;:=^:/Y%>9[R34+K\B==U']$ZCH5W<#][)HFK3>O%Z6V\<WWU
M_>9M,^H&<`G8HQA[?%^:O_.1VO\`HZ=H/_.,%UY2OYB8YO,/G;S+HT>F68H:
M2^EHT^H7=R?\B.*,?\691'@(N_Q^.]CEE3/X/*?G31?*6LO=^<=1\V^>]9NH
MKR[OX?\`0;:.8^G#]6T^S]7TK6VBB!'`F20_WDDDDN^:;M*$^<7(TV_-[)'&
M8XEC21Y?3']Y(WJ2?><RY0D8,<<XEY9IMMYY3S):37TTXT(:OJ\C(S=+7T_]
M#]0^J?@!Z"G7-'BQY!D<N1AP^;+O.XUB7RQJD?E^26/6Q''^CC"U)*^I'7K[
M5S9ZXRAI^(<Q7WN-AC:>:4URNGVBW1;ZQZ?[[GCH)2G@XCSW7-&N3S_18_.,
M/G+5;C4);J3RU<27B:?!(T91*?53#)2H/#^__P`_3S6SGDCG`\W)R&'"*9GK
MJZC+IEY;:9))%?7E;:&[3_CW];;UO^>77-OK^(8K#CB<;"CY6EUA]`TH:["\
M&LQP&/4%Y@\Y828O4V[2TYC*-!&63%<DZB48RVY)!:V'F1_.^K7]SJL]MY=M
M6A_1]A\,D5URM:25KO'Z4HY^^8VEC/QB&R4HF`V37SNNNRZ)P\O221:F+ZPH
M8>OH_6HO7Z]O2YY9KQ+B%-6``\V1:>9C8VOU@MZWH1^KS^WZE-Z_3F9AA(P%
MHS"N3S?18O-Z>9+-=1-Y)I<<^N&[D>2,V[QR3Q'3]AOM%SV['-%##FCF`\_)
MRLY@!LRGSG%JMSY7UU=!DGCUD6<WZ*-N_IR?6?2/I;GWS9=K^)##<2TX91O=
MD5M']7MT3G+)P2M9F]27Z<S("9@TP"0>74U5+KS.-3]?T)-7D;2!,W_'KZ,5
M/2IT'J\\ITPD)%9A`:O%K<OF6R%;@^7);%XZV<GIR0WIF`]24U'P>GL/]EF+
MK)3&8!MIE.H&62RO8X6DCF]"3TY(?[WG3_==??-CJ8R&*QS:R'Q[_P`Y-V/Y
MK^8O^<;?/7Y;>5OR\U+SYY\\\:7=:#:S6ES:6UM'%<2^A];NI;Z['I_NCZGI
M@R>&3[#S`:JY;`#]"=3$='E7_.'VH?GI^1OY"^3?RE_,'_G&7SC=:SY/>_MH
M=0T+4?+=S;W%K-=2WD,A];6;?TW'K>G3_)S<=H&.347$[?L<;%L7O%AYZ_/3
MSQ^9WD;0X_R/US\M/RQTZ2ZU3SMYPU_4M&>XNI(;63ZI80V>FWET>$MS(DDD
MG^13,(Q`'-N?5]<J13__U_OIBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
4KL5=BKL5=BKL5=BKL5=BKL5?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
